Guardant Health Beheer
Beheer criteriumcontroles 4/4
De CEO Guardant Health is Helmy Eltoukhy, benoemd in Jan2013, heeft een ambtstermijn van 11.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.59K, bestaande uit 0.01% salaris en 100% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.13% van de aandelen van het bedrijf, ter waarde $ 81.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 3.2 jaar.
Belangrijke informatie
Helmy Eltoukhy
Algemeen directeur
US$11.6k
Totale compensatie
| Percentage CEO-salaris | 0.009% |
| Dienstverband CEO | 11.8yrs |
| Eigendom CEO | 2.1% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 3.2yrs |
Recente managementupdates
Recent updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 24Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$512m |
| Jun 30 2024 | n/a | n/a | -US$491m |
| Mar 31 2024 | n/a | n/a | -US$461m |
| Dec 31 2023 | US$12k | US$1 | -US$479m |
| Sep 30 2023 | n/a | n/a | -US$432m |
| Jun 30 2023 | n/a | n/a | -US$508m |
| Mar 31 2023 | n/a | n/a | -US$665m |
| Dec 31 2022 | US$12k | US$1 | -US$655m |
| Sep 30 2022 | n/a | n/a | -US$606m |
| Jun 30 2022 | n/a | n/a | -US$551m |
| Mar 31 2022 | n/a | n/a | -US$419m |
| Dec 31 2021 | US$14k | US$1 | -US$406m |
| Sep 30 2021 | n/a | n/a | -US$409m |
| Jun 30 2021 | n/a | n/a | -US$379m |
| Mar 31 2021 | n/a | n/a | -US$336m |
| Dec 31 2020 | US$114m | US$210k | -US$254m |
| Sep 30 2020 | n/a | n/a | -US$185m |
| Jun 30 2020 | n/a | n/a | -US$120m |
| Mar 31 2020 | n/a | n/a | -US$77m |
| Dec 31 2019 | US$915k | US$500k | -US$76m |
| Sep 30 2019 | n/a | n/a | -US$76m |
| Jun 30 2019 | n/a | n/a | -US$87m |
| Mar 31 2019 | n/a | n/a | -US$97m |
| Dec 31 2018 | US$818k | US$480k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$75m |
| Jun 30 2018 | n/a | n/a | -US$84m |
| Mar 31 2018 | n/a | n/a | -US$83m |
| Dec 31 2017 | US$4m | US$460k | -US$89m |
Compensatie versus markt: De totale vergoeding ($USD 11.59K ) Helmy } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.60M ).
Compensatie versus inkomsten: De vergoeding van Helmy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Helmy Eltoukhy (45 yo)
11.8yrs
Tenure
US$11,591
Compensatie
Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$11.59k | 2.13% $ 81.6m | |
| Co-CEO & Director | 3.3yrs | US$26.42k | 2.2% $ 84.4m | |
| Chief Financial Officer | 3.8yrs | US$4.12m | 0.019% $ 746.0k | |
| Chief Technology Officer | no data | US$4.76m | 0.044% $ 1.7m | |
| Chief Medical Officer | 3.5yrs | US$3.49m | 0.019% $ 720.8k | |
| Chief Commercial Officer | 3.4yrs | US$3.52m | 0.025% $ 974.5k | |
| Chief Information Officer | 4.8yrs | geen gegevens | 0.014% $ 549.7k | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 4.5yrs | US$6.02m | 0.027% $ 1.0m | |
| Senior Vice President of Public Affairs | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Marketing | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | less than a year | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$11.59k | 2.13% $ 81.6m | |
| Co-CEO & Director | 11.8yrs | US$26.42k | 2.2% $ 84.4m | |
| Independent Director | 3.1yrs | US$425.21k | 0.011% $ 423.0k | |
| Lead Independent Director | 7.8yrs | US$470.21k | 0.0068% $ 261.4k | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 2.4yrs | US$425.21k | 0.0080% $ 307.0k | |
| Independent Director | 1.7yrs | US$725.30k | 0.0040% $ 154.6k | |
| Independent Director | 4.4yrs | US$425.21k | 0.014% $ 546.6k | |
| Independent Director | 3.3yrs | US$425.21k | 0.0062% $ 236.9k | |
| Director | less than a year | geen gegevens | geen gegevens |
3.2yrs
Gemiddelde duur
50.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).